International: +1-347-960-6455
Interleukin-6 (IL-6) Inhibitors Pipeline to Witness Growth due to Positive Clinical Results in the Coming Years

According to a new research report Interleukin-6 (IL-6) Inhibitors – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, IL-6 inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates.

IL-6 Inhibitors Pipeline Insights

IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6α receptor. This protein is assumed to be actively involved in pyrogenesis, cancer, rheumatoid arthritis, diabetes mellitus, and schizophrenia. The IL-6 inhibitors target the IL-6 receptors, thereby blocking the signaling pathway between receptors and mediators of inflammation that stimulate the accumulation of B cells.

Some of the approved medications acting as antagonists of IL-6 include Actmera (F. Hoffmann-La Roche Ltd.), Kevzara (Regeneron Pharmaceuticals Inc. and Sanofi-aventis Groupe), and Sylvant (Janssen Global Services LLC).

Insights into Pipeline Segments

According to the research, drugs being developed as IL-6 inhibitors, most of which are in clinical phases and can be expected to be given orally. It has been observed that the oral route of medications is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance.

Positive Clinical Trial Results Play a Pivotal Role in IL-6 Inhibitors Pipeline

Companies that are involved in developing anti-IL-6 therapeutics have shown positive clinical results in the various phases of drug development. For instance, in May 2015, Regeneron Pharmaceuticals Inc. and Sanofi-aventis Groupe announced positive data of phase III trial of sarilumab (Kevzara) for the treatment of patients with rheumatoid arthritis. The results of the study concluded that treatment with sarilumab has a favorable safety and tolerability profile, leading to the improvement of signs and symptoms of rheumatoid arthritis as compared to placebo.

Browse Detailed Report at:

Designations Granted by Regulatory Authorities will Help the IL-6 Inhibitors Market to Grow

In June 2015, the U.S. Food and Drug Administration (USFDA) granted Breakthrough Therapy Designation to F. Hoffmann-La Roche Ltd.’s Actmera for the treatment of systemic sclerosis. Thus, such designation paces up the development process of the drug and helps it to reach the market sooner. Therefore, the designations will help the market to grow significantly.

Some of the companies involved in the development of IL-6 inhibitors include F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Sanofi-aventis Groupe, Janssen Global Services LLC, Novimmune SA, UCB Pharma.

IL-6 Inhibitors Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of IL-6 inhibitors under development. Comprehensive insights on the pipeline phase products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies developing IL-6 inhibitors. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to IL-6 inhibitors.